These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27771612)

  • 1. Oncology drug costs-the imaginary crisis?
    Turck R
    Ann Oncol; 2017 Feb; 28(2):427-431. PubMed ID: 27771612
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cost/benefit analysis of cancer drugs].
    Jordan B
    Med Sci (Paris); 2020 Nov; 36(11):1095-1097. PubMed ID: 33151876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The high cost of cancer drugs and what we can do about it.
    Siddiqui M; Rajkumar SV
    Mayo Clin Proc; 2012 Oct; 87(10):935-43. PubMed ID: 23036669
    [No Abstract]   [Full Text] [Related]  

  • 4. Overspending driven by oversized single dose vials of cancer drugs.
    Bach PB; Conti RM; Muller RJ; Schnorr GC; Saltz LB
    BMJ; 2016 Feb; 352():i788. PubMed ID: 26932932
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug assistance programs for the cancer patient.
    Mowad LZ; Richter SS
    Cancer Pract; 2000; 8(1):49-50. PubMed ID: 10732540
    [No Abstract]   [Full Text] [Related]  

  • 6. Cancer drugs in China: affordability and creativity.
    The Lancet
    Lancet; 2018 May; 391(10133):1866. PubMed ID: 29781431
    [No Abstract]   [Full Text] [Related]  

  • 7. Paying a high price for cancer drugs.
    Lancet; 2015 Aug; 386(9992):404. PubMed ID: 26251376
    [No Abstract]   [Full Text] [Related]  

  • 8. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
    Prasad V; Mailankody S
    Mayo Clin Proc; 2016 Jun; 91(6):707-12. PubMed ID: 27261866
    [No Abstract]   [Full Text] [Related]  

  • 9. In Cancer Care, Can We Afford To Hope?
    Hafner Z
    Manag Care; 2018 May; 27(5):31. PubMed ID: 29763406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Charting the Course: Use of Clinical Pathways to Improve Value in Cancer Care.
    Malin JL
    J Clin Oncol; 2020 Feb; 38(4):367-371. PubMed ID: 31804871
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacoeconomic analyses make way into oncology.
    Amber D
    J Natl Cancer Inst; 2000 Aug; 92(15):1204-5. PubMed ID: 10922402
    [No Abstract]   [Full Text] [Related]  

  • 12. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
    Tefferi A; Kantarjian H; Rajkumar SV; Baker LH; Abkowitz JL; Adamson JW; Advani RH; Allison J; Antman KH; Bast RC; Bennett JM; Benz EJ; Berliner N; Bertino J; Bhatia R; Bhatia S; Bhojwani D; Blanke CD; Bloomfield CD; Bosserman L; Broxmeyer HE; Byrd JC; Cabanillas F; Canellos GP; Chabner BA; Chanan-Khan A; Cheson B; Clarkson B; Cohn SL; Colon-Otero G; Cortes J; Coutre S; Cristofanilli M; Curran WJ; Daley GQ; DeAngelo DJ; Deeg HJ; Einhorn LH; Erba HP; Esteva FJ; Estey E; Fidler IJ; Foran J; Forman S; Freireich E; Fuchs C; George JN; Gertz MA; Giralt S; Golomb H; Greenberg P; Gutterman J; Handin RI; Hellman S; Hoff PM; Hoffman R; Hong WK; Horowitz M; Hortobagyi GN; Hudis C; Issa JP; Johnson BE; Kantoff PW; Kaushansky K; Khayat D; Khuri FR; Kipps TJ; Kripke M; Kyle RA; Larson RA; Lawrence TS; Levine R; Link MP; Lippman SM; Lonial S; Lyman GH; Markman M; Mendelsohn J; Meropol NJ; Messinger Y; Mulvey TM; O'Brien S; Perez-Soler R; Pollock R; Prchal J; Press O; Radich J; Rai K; Rosenberg SA; Rowe JM; Rugo H; Runowicz CD; Sandmaier BM; Saven A; Schafer AI; Schiffer C; Sekeres MA; Silver RT; Siu LL; Steensma DP; Stewart FM; Stock W; Stone R; Storb R; Strong LC; Tallman MS; Thompson M; Ueno NT; Van Etten RA; Vose JM; Wiernik PH; Winer EP; Younes A; Zelenetz AD; LeMaistre CA
    Mayo Clin Proc; 2015 Aug; 90(8):996-1000. PubMed ID: 26211600
    [No Abstract]   [Full Text] [Related]  

  • 13. Economic burden of cancer across the European Union: a population-based cost analysis.
    Luengo-Fernandez R; Leal J; Gray A; Sullivan R
    Lancet Oncol; 2013 Nov; 14(12):1165-74. PubMed ID: 24131614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World.
    Goldstein DA; Sarfaty M
    Oncologist; 2016 Aug; 21(8):907-9. PubMed ID: 27384235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seeking value as cancer drug costs soar.
    Bender E
    Cancer Discov; 2013 Aug; 3(8):833-4. PubMed ID: 23928760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value in Oncology: It Is in the Eyes of the Beholder.
    Nabhan C; Phillips EG; Feinberg BA
    J Natl Compr Canc Netw; 2019 Jan; 17(1):2-5. PubMed ID: 30659123
    [No Abstract]   [Full Text] [Related]  

  • 17. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 18. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
    [No Abstract]   [Full Text] [Related]  

  • 19. Cancer drug prices and the free-market forces.
    Kantarjian H; Zwelling L
    Cancer; 2013 Nov; 119(22):3903-5. PubMed ID: 24037953
    [No Abstract]   [Full Text] [Related]  

  • 20. Era of personalized medicine may herald end of soaring cancer costs.
    Keogh B
    J Natl Cancer Inst; 2012 Jan; 104(1):12-3, 16-7. PubMed ID: 22173586
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.